- Home
- XTLB
as 11-21-2024 4:00pm EST
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
Upcoming Earnings Alert:
Get ready for potential market movements as XTL Biopharmaceuticals Ltd. XTLB prepares to release earnings report on 26 Nov 2024.
| Founded: | 1993 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 8.0M | IPO Year: | 2005 |
| Target Price: | N/A | AVG Volume (30 days): | 109.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.76 - $4.99 | Next Earning Date: | 11-26-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest XTL Biopharmaceuticals Ltd. News
XTLB Breaking Stock News: Dive into XTLB Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 months ago
XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million
MT Newswires
6 months ago
XTL Biopharmaceuticals Signs Deal to Acquire The Social Proxy
GlobeNewswire
6 months ago
XTL Entered Definitive Agreement to Acquire The Social Proxy
GlobeNewswire
8 months ago
XTL To Aquire The Social Proxy
GlobeNewswire
10 months ago
Sound Group Inc. Announces Trading under New Name on Nasdaq
GlobeNewswire
10 months ago
Sound Group Inc. (Formerly LIZHI INC.) Announces Corporate Name and Ticker Symbol Change
Insider Monkey
10 months ago
CONSOL Energy (CEIX) Returned 61% Despite 25% Fall in Estimates
Business Wire
10 months ago
AG Mortgage Investment Trust, Inc. Announces Pricing of Public Offering of Senior Notes
Compare XTLB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XTLB XTL Biopharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.